$ARDX News

Wedbush Reiterates Outperform on Ardelyx, Maintains $9 Price Target

Wedbush Reiterates Outperform on Ardelyx, Maintains $9 Price Target

Piper Sandler Maintains Overweight on Ardelyx, Lowers Price Target to $15

Ardelyx Q2: Strong Demand, But Payer Friction Clouds The Story

Citigroup Maintains Buy on Ardelyx, Lowers Price Target to $11

TD Cowen Maintains Buy on Ardelyx, Lowers Price Target to $10

Ardelyx, Inc. (ARDX) Q2 2026 Earnings Call Transcript

BTIG Maintains Buy on Ardelyx, Lowers Price Target to $14

Ardelyx (NASDAQ:ARDX) Plunges After Q2 Miss and Guidance Cut

Ardelyx Q2 EPS $(0.07) Misses $(0.05) Estimate, Sales $118.100M Miss $121.601M Estimate

Will Ardelyx (ARDX) Report Negative Earnings Next Week? What You Should Know

New Cross-Study Analysis from Spherix Global Insights Combines Physician, Dietitian and Patient Chart Data to Show Access Barriers Still Curbing Xphozah Uptake Ahead of the TDAPA Cliff

Ardelyx to Report Second Quarter 2026 Financial Results on August 6, 2026

Claude AI Says Market is Ignoring Ardelyx (ARDX) Growth Catalysts

Ardelyx: The Market Is Right To Discount This Revenue Growth

ARDX Stock Tumbles As Xphozah Loses Final Medicare Reimbursement Battle

Ardelyx Stock Up 70%: What to Know About This $490,000 Insider Transaction

What’s Fueling Optimism Around Ardelyx, Inc. (ARDX)’s Sales and Pipeline?

Ladenburg Thalmann Assumes Ardelyx at Buy, Announces Price Target of $16

Ardelyx (ARDX) Stock Valuation Check After Recent Share Price Volatility